INNATE PHARMA SA (IPHA): Price and Financial Metrics


INNATE PHARMA SA (IPHA): $6.70

-0.30 (-4.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IPHA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 481

in industry

IPHA Stock Summary

  • IPHA's went public 1.94 years ago, making it older than merely 3.25% of listed US stocks we're tracking.
  • In terms of twelve month growth in earnings before interest and taxes, Innate Pharma SA is reporting a growth rate of 402.37%; that's higher than 94.11% of US stocks.
  • As for revenue growth, note that IPHA's revenue has grown -37.7% over the past 12 months; that beats the revenue growth of merely 6.91% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Innate Pharma SA are AUMN, FF, SNCR, LMNL, and RBBN.
  • IPHA's SEC filings can be seen here. And to visit Innate Pharma SA's official web site, go to www.innate-pharma.com.

IPHA Stock Price Chart Interactive Chart >

Price chart for IPHA

IPHA Price/Volume Stats

Current price $6.70 52-week high $11.95
Prev. close $7.00 52-week low $3.02
Day low $6.56 Volume 222,300
Day high $7.13 Avg. volume 843,577
50-day MA $4.30 Dividend yield N/A
200-day MA $4.26 Market Cap 530.40M

INNATE PHARMA SA (IPHA) Company Bio


Innate Pharma SA is a biopharmaceutical company, which focuses on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. Its products include immunotherapy drugs and monoclonal antibodies. The Immunotherapy drugs are designated for cancer and inflammatory diseases. The Monoclonal antibodies targets receptors and pathways controlling the activation of innate immunity cells.


IPHA Latest News Stream


Event/Time News Detail
Loading, please wait...

IPHA Latest Social Stream


Loading social stream, please wait...

View Full IPHA Social Stream

Latest IPHA News From Around the Web

Below are the latest news stories about Innate Pharma SA that investors may wish to consider to help them evaluate IPHA as an investment opportunity.

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferre

Yahoo | September 23, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | September 21, 2021

48 Biggest Movers From Friday

Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer. Helbiz, Inc. (NASDAQ: HLBZ) shares surged 96.6% to close at $17.69 on Friday after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.

Yahoo | September 20, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

There's only one day of trading left so let's start it off right with a look at the biggest pre-market stock movers for Friday.

William White on InvestorPlace | September 17, 2021

What Is Happening With Innate Pharma Stock On Friday?

Innate Pharma SA (NASDAQ: IPHA ) stock is trading at a 52-week high as its partner AstraZeneca Plc (NASDAQ: AZN ) presented results from the COAST Phase 2 trial during the European Society for Medical Oncology ( ESMO21 ) Congress 2021. The trial included patients with unresectable, Stage 3 non-small cell lung cancer (NSCLC) who had not progressed after concurrent chemoradiation therapy (CRT). After a median follow-up of 11.5 months, Imfinzi (durvalumab) plus oleclumab reduced the risk of disease progression or death by 56% (hazard ratio [HR] = 0.44), Imfinzi plus monalizumab Full story available on Benzinga.com

Benzinga | September 17, 2021

Read More 'IPHA' Stories Here

IPHA Price Returns

1-mo 98.05%
3-mo 94.20%
6-mo 54.38%
1-year 73.35%
3-year N/A
5-year N/A
YTD 63.81%
2020 -36.49%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8412 seconds.